News

Latest updates from Engimata

We are now located in Livermore, CA.

Engimata’s breakthrough research on “A versatile room temperature stable lipid nanoparticle COVID-19 protein-based vaccine”. was presented at the 2022 Colorado Protein Stability Conference in Breckenridge, Colorado on Aug 10th by Dr. Mitra Mosharraf. Other co-authors were Dr. Aryo Sorayya and Dr Rajiv Nayar.  

Engimata is proud to announce that it was granted a US patent for its COVID-19 vaccine.
This patent is a step forward towards a thermostable COVID-19 vaccine which can be distributed at room temperature. It is also the second patent that Engimata received for its vaccine adjuvant platform.

Patent: Mosharraf, M., Sorayya, A., and Nayar, R., Immunogenic Composition Forming a SARS-COV-2 Vaccine, and a method for its manufacture, US Patent 11278617.Granted March 22, 2022.
For any inquiries, please contact us.

The Pleasanton Chamber of Commerce and the City of Pleasanton have joined in recognizing three local businesses as economic drivers for 2021: Engimata, a biotech company involved in the production of vaccines; IrisVision Global, which is developing wearable devices for the visually impaired; and Paxon Energy & Infrastructure, a planning, training and support services company for the oil, gas and utility industries.

The Chamber's Business Connection newsletter is a bi-montly publication inserted into the Pleasanton Weekly on the first Friday of the odd-numbered months. It features business spotlights on members, a column by the board chair, membership anniversaries, ribbon cuttings and more. 
​​​​​​​
Engimata Article (PDF)
Business Connection Newsletter

"Dr. Mitra Mosharraf MBA ’20 CEO of Engimata, Inc. is working to improve vaccine efficiency and enhance vaccine stability. Advice to women entrepreneurs: “Do not be afraid to fail. Failure is just a new starting point that helps us grow until we find the right path.”
Original Post

There is an urgent need for a COVID-19 vaccine. Currently, multiple COVID-19 vaccines are in various stages of development, with Moderna, Pfizer, Sanofi, Johnson & Johnson and AstraZenecca at the frontline. Both Moderna and Pfizer are developing mRNA vaccines that must be stored and transported at -70 °C or -20 °C. This greatly limits their distribution throughout the world because of the complicated and expensive supply chain needed to distribute these vaccines*.

Engimata has focused on development of vaccines that can be transported and stored outside the cold supply chain. We have recently developed a thermostable COVID-19 vaccine that, unlike other vaccines being developed, does not require a complicated cold-chain for transportation and distribution.
​​​​​​​
Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.